Navigation Links
Boston Scientific Announces Results for First Quarter Ended March 31, 2008
Date:4/21/2008

NATICK, Mass., April 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2008, as well as guidance for net sales and earnings per share (EPS) for the second quarter of 2008.

First quarter highlights:

-- Achieved net sales of $2.046 billion and adjusted EPS of $0.24

-- Improved earnings through ongoing, stringent expense management

-- Maintained leading position in the worldwide drug-eluting stent (DES)

market

-- Received approval for six cardiac rhythm management (CRM) products

-- Grew Neuromodulation sales 40 percent

-- Increased Endosurgery sales nine percent

-- Completed the sale of five non-strategic businesses

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Our earnings benefited from our ongoing expense management and were also helped by favorable tax items. Despite the arrival of a third DES competitor in the United States, we held our leadership positions in both the U.S. and worldwide markets. Our six CRM product approvals were exciting news, and they will contribute to our future growth in that market. The performance of our Neuromodulation group was impressive, and our Endosurgery group turned in another solid quarter. Our progress furthered our goals of restoring profitable sales growth, increasing shareholder value and strengthening Boston Scientific for the future."

Net sales for the first quarter of 2008 were $2.046 billion, including sales from divested businesses of $32 million, as compared to $2.086 bi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The report ... Management Market by Product Type & Provider ... Analysis (2014-2019)” defines and segments the market ... revenues. , Browse 152 market data ... and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation ... Medtronic, Inc. (NYSE: MDT ) has ... Food and Drug Administration (FDA) for the use ... infusion system (including a newly developed catheter) for ... Injection delivered intravenously to patients with pulmonary arterial ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing ... common stock, and warrants to purchase up to an ... price of $4.00 per share and $.01 per warrant.  ... $5.00, are exercisable immediately, and expire 5 years from ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... 25 Inverness Medical,Innovations, Inc. (Amex: IMA ... products for the consumer and professional markets, announced,today ... Global Healthcare,Unplugged Conference being held April 30 - ... Florida. Ron Zwanziger, Chief Executive Officer, will,attend. His ...
... 25 Abbott,s broad,portfolio of businesses and expanding ... product pipeline provides a,foundation for continued growth as ... Chief Executive Officer Miles D.,White told shareholders today ... an outstanding year for Abbott across all of ...
... -- China Yingxia,International, Inc. (OTC Bulletin Board: ... provider in the nutraceutical industry engaged in ... food,products, supplements, and personal care products in ... that it has formally completed the,acquisition of ...
Cached Biology Technology:Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 2Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 3Abbott Annual Meeting Highlights Outstanding 2007 Results, International Growth and Near-Term Pipeline 4China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 2China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network 3
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... infectious question about eating at restaurants: How clean are ... found that even when they washed dishes in cooler-than-recommended ... levels accepted in the Food and Drug Administration's Food ... milk—can be safe havens for bacteria when dried onto ...
... What influence does the variation in estrogen level ... Using functional Magnetic Resonance Imaging, Jean-Claude Dreher, a ... 1), in collaboration with an American team from ... directed by Karen Berman, has identified, for the ...
... patients who received an new intravenous adult stem cell ... such as cardiac arrhythmias, and had significant improvements in ... received a placebo, according to six-month Phase I study ... in Intervention: i2Summit in New Orleans on March 25. ...
Cached Biology News:Manual dishwashing study digs up dirt on dish cleanliness 2Manual dishwashing study digs up dirt on dish cleanliness 3The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4Stem cell therapy shows promise in regenerating damaged muscle in heart attack patients 2